New drug tested for Tough-to-Treat blood cancers
NCT ID NCT04874480
Summary
This is an early safety study testing a new drug called tegavivint in adults with leukemia that has returned or hasn't responded to other treatments. The main goals are to find the highest safe dose and understand the side effects. Researchers will also check if the drug, sometimes given with another medication, can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.